Interpretation of Consensus on Diagnosis and Management of Cushing's Disease: a Guideline Update of the International Pituitary Society——Diagnosis

doi:10.12114/j.issn.1007-9572.2022.0190

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (20): 2435-2442.DOI: 10.12114/j.issn.1007-9572.2022.0190

Special Issue: 指南/共识最新文章合辑

• Guide Interpretation • Next Articles

Interpretation of Consensus on Diagnosis and Management of Cushing's Disease: a Guideline Update of the International Pituitary Society——Diagnosis

¹Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu 610041, China
²Institute of Pituitary Adenomas and Related Diseases Center, West China Hospital, Sichuan University, Chengdu 610041, China

Received:2022-02-15 Revised:2022-03-20 Published:2022-07-15 Online:2022-05-19
Contact: Yerong YU
About author:
TAN H W, TANG Y, YU Y R, et al. Interpretation of Consensus on Diagnosis and Management of Cushing's Disease: a Guideline Update of the International Pituitary Society——diagnosis[J]. Chinese General Practice, 2022, 25 (20) : 2435-2442.

国际垂体协会《库欣病的诊断和管理共识（更新版）》解读——诊断篇

¹610041　四川省成都市，四川大学华西医院内分泌代谢科
²610041　四川省成都市，四川大学华西医院垂体瘤及相关疾病诊疗中心

通讯作者: 余叶蓉
作者简介:
谭惠文，唐宇，余叶蓉，等.国际垂体协会《库欣病的诊断和管理共识（更新版）》解读——诊断篇[J].中国全科医学，2022，25（20）：2435-2442. [www.chinagp.net] 作者贡献：谭惠文、余叶蓉提出主要研究内容及目的，负责文章的构思与设计；余叶蓉、李建薇、李佳琦、安振梅、王椿、魏懿进行研究的实施与可行性分析；谭惠文、唐宇进行文献整理、论文撰写和修改，绘制图表；余叶蓉负责文章的质量控制及审校、监督管理。
基金资助:
四川大学华西医院学科卓越发展1·3·5工程临床研究孵化项目(2020HXFH034); 四川省卫生健康委员会项目(20PJ046)

Abstract

Abstract:

Cushing disease, the most common cause of endogenous Cushing's syndrome characterized by hypercortisolemia, is a clinical syndrome caused by adrenocorticotropic hormone (ACTH) ——secreting pituitary adenomas. The excessive secretion of ACTH in Cushing's disease stimulates bilateral adrenal hyperplasia and causes hypercortisolemia, which can lead to a series of severe clinical syndromes such as electrolyte imbalance, glucose and lipid metabolism disorders, involving multiple organs and systems in the body. The clinical symptoms of Cushing's disease are complex and diverse, and its diagnosis and treatment are extremely challenging. In December 2021, the International Pituitary Society released the Consensus on Diagnosis and Management of Cushing's Disease: a Guideline Update, which focuses on the complications and comorbidities of Cushing's disease, such as hypercoagulability, cardiovascular disease, metabolic bone disease, growth hormone deficiency and infection, etc.; discusses the application of the latest evidence in clinical practice, with a particular focus on new treatment and screening options, diagnostic algorithms, and best practices for preventing disease recurrence. Based on the latest evidence-based medical evidence, this article focuses on the interpretation of Cushing's disease——related laboratory examinations, imaging examinations, diagnosis and treatment management procedures, and recurrence monitoring discussed in the Consensus on Diagnosis and Management of Cushing's Disease: a Guideline Update, in order to improve the general practitioners and specialists'understanding of this syndrome and improve the prognosis of patients with Cushing's disease.

Key words: Cushing syndrome, Cushing disease, Diagnostic and treatment guideline, Pituitary adenoma, Diagnostic techniques and procedures, Therapy

摘要：

库欣病是以高皮质醇血症为特征的内源性库欣综合征最常见的病因，是由分泌促肾上腺皮质激素（ACTH）的垂体腺瘤引起的临床综合征。库欣病过度分泌的ACTH刺激双侧肾上腺皮质增生并引起高皮质醇血症，可导致电解质紊乱，糖、脂代谢紊乱等一系列严重的临床症候群，累及全身多个脏器及系统。库欣病临床症状复杂多样，其诊断和治疗极具挑战性。国际垂体协会在2021年12月发布了《库欣病的诊断和管理共识（更新版）》，该指南更新关注库欣病的并发症和合并症，诸如高凝状态、心血管疾病、骨代谢疾病、生长激素缺乏及感染等；讨论了最新证据在临床实践中的应用，尤其侧重于新的治疗选择、筛查、诊断算法以及防治疾病复发的最佳实践。本文立足于最新的循证医学证据，对《库欣病的诊断和管理共识（更新版）》讨论的库欣病相关的实验室检查、影像学检查、诊断和治疗管理流程及复发监测等多方面进行重点解读，以期提高广大全科及专科医师对库欣病的理解，更好地指导规范化的诊疗，改善库欣病患者预后。

关键词: 库欣综合征, 库欣病, 诊疗指南, 垂体腺瘤, 诊断技术和方法, 治疗

Huiwen TAN,Yu TANG,Yerong YU, et al. Interpretation of Consensus on Diagnosis and Management of Cushing's Disease: a Guideline Update of the International Pituitary Society——Diagnosis[J]. Chinese General Practice, 2022, 25(20): 2435-2442. DOI: 10.12114/j.issn.1007-9572.2022.0190.
谭惠文,唐宇,余叶蓉等. 国际垂体协会《库欣病的诊断和管理共识（更新版）》解读——诊断篇[J]. 中国全科医学, 2022, 25(20): 2435-2442. DOI: 10.12114/j.issn.1007-9572.2022.0190.

Figures/Tables 2

References 63

[1]	FLESERIU M，AUCHUS R，BANCOS I，et al. Consensus on diagnosis and management of Cushing's disease：a guideline update[J]. Lancet Diabetes Endocrinol，2021，9（12）：847-875. DOI：10.1016/S2213-8587(21)00235-7.
[2]	NIEMAN L K，BILLER B M K，FINDLING J W，et al. The diagnosis of Cushing's syndrome：an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab，2008，93（5）：1526-1540. DOI：10.1210/jc.2008-0125.
[3]	NIEMAN L K，BILLER B M，FINDLING J W，et al. Treatment of Cushing's syndrome：an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab，2015，100（8）：2807-2831. DOI：10.1210/jc.2015-1818.
[4]	RAFF H，PHILLIPS J M. Bedtime salivary cortisol and cortisone by LC-MS/MS in healthy adult subjects：evaluation of sampling time[J]. J Endocr Soc，2019，3（8）：1631-1640. DOI：10.1210/js.2019-00186.
[5]	PETERSENN S. Biochemical diagnosis of Cushing's disease：screening and confirmatory testing[J]. Best Pract Res Clin Endocrinol Metab，2021，35（1）：101519. DOI：10.1016/j.beem.2021.101519.
[6]	GALM B P，QIAO N D，KLIBANSKI A，et al. Accuracy of laboratory tests for the diagnosis of cushing syndrome[J]. J Clin Endocrinol Metab，2020，105（6）：dgaa105. DOI：10.1210/clinem/dgaa105.
[7]	RAFF H，AUCHUS R J，FINDLING J W，et al. Urine free cortisol in the diagnosis of Cushing's syndrome：is it worth doing and，if so，how? [J]. J Clin Endocrinol Metab，2015，100（2）：395-397. DOI：10.1210/jc.2014-3766.
[8]	MOFFAT S D，AN Y，RESNICK S M，et al. Longitudinal change in cortisol levels across the adult life span[J]. J Gerontol A Biol Sci Med Sci，2020，75（2）：394-400. DOI：10.1093/gerona/gly279.
[9]	RAFF H，COHEN E P，FINDLING J W. A commentary on Diagnosing Cushing's disease in the context of renal failure[J]. Eur J Endocrinol，2019，181（4）：C9-11. DOI：10.1530/EJE-19-0560.
[10]	OKI Y，HASHIMOTO K，HIRATA Y，et al. Development and validation of a 0.5 mg dexamethasone suppression test as an initial screening test for the diagnosis of ACTH-dependent Cushing's syndrome[J]. Endocr J，2009，56（7）：897-904. DOI：10.1507/endocrj.k09e-194.
[11]	李佳琦，孙丽思，余叶蓉. 库欣综合征筛查试验的选择和临床应用[J]. 国际内分泌代谢杂志，2021，41（6）：573-577. DOI：10.3760/cma.j.cn121383-20210831-08083.
[12]	YANOVSKI J A，CUTLER G B，DOPPMAN J L，et al. The limited ability of inferior petrosal sinus sampling with corticotropin-releasing hormone to distinguish Cushing's disease from pseudo-Cushing states or normal physiology[J]. J Clin Endocrinol Metab，1993，77（2）：503-509. DOI：10.1210/jcem.77.2.8393887.
[13]	ALEXANDRAKI K I，KALTSAS G A，ISIDORI A M，et al. The prevalence and characteristic features of cyclicity and variability in Cushing's disease[J]. Eur J Endocrinol，2009，160（6）：1011-1018. DOI：10.1530/EJE-09-0046.
[14]	CECCATO F，BOSCARO M. Cushing's syndrome：screening and diagnosis[J]. High Blood Press Cardiovasc Prev，2016，23（3）：209-215. DOI：10.1007/s40292-016-0153-4.
[15]	LORIAUX D L. Diagnosis and differential diagnosis of Cushing's syndrome[J]. N Engl J Med，2017，376（15）：1451-1459. DOI：10.1056/NEJMra1505550.
[16]	BARNETT R. Cushing's syndrome[J]. Lancet，2016，388（10045）：649. DOI：10.1016/S0140-6736(16)31280-6.
[17]	BÄCKLUND N，BRATTSAND G，ISRAELSSON M，et al. Reference intervals of salivary cortisol and cortisone and their diagnostic accuracy in Cushing's syndrome[J]. Eur J Endocrinol，2020，182（6）：569-582. DOI：10.1530/EJE-19-0872.
[18]	GUO Q H，YOUNG W F，ERICKSON D，et al. Usefulness of dynamic MRI enhancement measures for the diagnosis of ACTH-producing pituitary adenomas[J]. Clin Endocrinol （Oxf），2015，82（2）：267-273. DOI：10.1111/cen.12475.
[19]	BUCHFELDER M，NISTOR R，FAHLBUSCH R，et al. The accuracy of CT and MR evaluation of the sella Turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease[J]. AJNR Am J Neuroradiol，1993，14（5）：1183-1190.
[20]	PATEL V，LIU C J，SHIROISHI M S，et al. Ultra-high field magnetic resonance imaging for localization of corticotropin-secreting pituitary adenomas[J]. Neuroradiology，2020，62（8）：1051-1054. DOI：10.1007/s00234-020-02431-x.
[21]	SENANAYAKE R，GILLETT D，MACFARLANE J，et al. New types of localization methods for adrenocorticotropic hormone-dependent Cushing's syndrome[J]. Best Pract Res Clin Endocrinol Metab，2021，35（1）：101513. DOI：10.1016/j.beem.2021.101513.
[22]	SHI X L，DU T T，ZHU D，et al. High-dose dexamethasone suppression test is inferior to pituitary dynamic enhanced MRI in the differential diagnosis of ACTH-dependent Cushing's syndrome[J]. Endocrine，2022，75（2）：516-524. DOI：10.1007/s12020-021-02891-y.
[23]	TSAGARAKIS S，TSIGOS C，VASILIOU V，et al. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome：constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion[J]. J Clin Endocrinol Metab，2002，87（4）：1646-1653. DOI：10.1210/jcem.87.4.8358.
[24]	NEWELL-PRICE J，PERRY L，MEDBAK S，et al. A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome[J]. J Clin Endocrinol Metab，1997，82（1）：176-181. DOI：10.1210/jcem.82.1.3674.
[25]	QIAO J T，LI J Q，ZHANG W W，et al. The usefulness of the combined high-dose dexamethasone suppression test and desmopressin stimulation test in establishing the source of ACTH secretion in ACTH-dependent Cushing's syndrome[J]. Endocr J，2021，68（7）：839-848. DOI：10.1507/endocrj.EJ20-0837.
[26]	QIAO J T，LI J Q，ZHANG W W，et al. The usefulness of the combined high-dose dexamethasone suppression test and desmopressin stimulation test in establishing the source of ACTH secretion in ACTH-dependent Cushing's syndrome[J]. Endocr J，2021，68（7）：839-848. DOI：10.1507/endocrj.EJ20-0837.
[27]	MILJIC D，JOKSIMOVIC M，DOKNIC M，et al. ACTH and cortisol responses to ghrelin and desmopressin in patients with Cushing's disease and adrenal enlargement[J]. J Endocrinol Invest，2010，33（8）：526-529. DOI：10.1007/BF03346641.
[28]	VASSILIADI D A，TSAGARAKIS S. DIAGNOSIS OF ENDOCRINE DISEASE：the role of the desmopressin test in the diagnosis and follow-up of Cushing's syndrome[J]. Eur J Endocrinol，2018，178（5）：R201-R214. DOI：10.1530/EJE-18-0007.
[29]	NEWELL-PRICE J，BERTAGNA X，GROSSMAN A B，et al. Cushing's syndrome[J]. Lancet，2006，367（9522）：1605-1617. DOI：10.1016/S0140-6736(06)68699-6.
[30]	SHARMA S T，RAFF H，NIEMAN L K. Prolactin as a marker of successful catheterization during IPSS in patients with ACTH-dependent Cushing's syndrome[J]. J Clin Endocrinol Metab，2011，96（12）：3687-3694. DOI：10.1210/jc.2011-2149.
[31]	VASSILIADI D A，MOURELATOS P，KRATIMENOS T，et al. Inferior petrosal sinus sampling in Cushing's syndrome：usefulness and pitfalls[J]. Endocrine，2021，73（3）：530-539. DOI：10.1007/s12020-021-02764-4.
[32]	茅江峰，柴晓峰，刘丽萍，等. 外周DDAVP兴奋试验在促肾上腺皮质激素依赖性库欣综合征鉴别诊断中的价值[J]. 中国实用内科杂志，2014，34（10）：1000-1003.
[33]	张微微，余叶蓉，谭惠文，等. 精氨酸血管加压素刺激试验与大剂量地塞米松抑制试验在库欣病与异位促肾上腺皮质激素综合征诊断中的价值[J]. 中华医学杂志，2016，96（11）：845-849. DOI：10.3760/cma.j.issn.0376-2491.2016.11.004.
[34]	HOFMAN M S，LAU W F E，HICKS R J. Somatostatin receptor imaging with ⁶⁸Ga DOTATATE PET/CT：clinical utility，normal patterns，pearls，and pitfalls in interpretation[J]. Radiographics，2015，35（2）：500-516. DOI：10.1148/rg.352140164.
[35]	DEPPEN S A，BLUME J，BOBBEY A J，et al. 68Ga-DOTATATE compared with ¹¹¹In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors：a systematic review and meta-analysis[J]. J Nucl Med，2016，57（6）：872-878. DOI：10.2967/jnumed.115.165803.
[36]	WANNACHALEE T，TURCU A F，BANCOS I，et al. The clinical impact of[68 Ga]-DOTATATE PET/CT for the diagnosis and management of ectopic adrenocorticotropic hormone - secreting tumours[J]. Clin Endocrinol （Oxf），2019，91（2）：288-294. DOI：10.1111/cen.14008.
[37]	SANTOS A，RESMINI E，MARTÍNEZ MOMBLÁN M A，et al. Quality of life in patients with Cushing's disease[J]. Front Endocrinol （Lausanne），2019，10：862. DOI：10.3389/fendo.2019.00862.
[38]	VAN DER PAS R，DE BRUIN C，LEEBEEK F W G，et al. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis，but is not reversible after short-term biochemical remission induced by medical therapy[J]. J Clin Endocrinol Metab，2012，97（4）：1303-1310. DOI：10.1210/jc.2011-2753.
[39]	STUIJVER D J，VAN ZAANE B，FEELDERS R A，et al. Incidence of venous thromboembolism in patients with Cushing's syndrome：a multicenter cohort study[J]. J Clin Endocrinol Metab，2011，96（11）：3525-3532. DOI：10.1210/jc.2011-1661.
[40]	WAGNER J，LANGLOIS F，LIM D S T，et al. Hypercoagulability and risk of venous thromboembolic events in endogenous Cushing's syndrome：a systematic meta-analysis[J]. Front Endocrinol （Lausanne），2018，9：805. DOI：10.3389/fendo.2018.00805.
[41]	SUAREZ M G，STACK M，HINOJOSA-AMAYA J M，et al. Hypercoagulability in cushing syndrome，prevalence of thrombotic events：a large，single-center，retrospective study [J]. J Endocr Soc，2020，4（2）：bvz033. DOI：10.1210/jendso/bvz033.
[42]	ZILIO M，MAZZAI L，SARTORI M T，et al. A venous thromboembolism risk assessment model for patients with Cushing's syndrome[J]. Endocrine，2016，52（2）：322-332. DOI：10.1007/s12020-015-0665-z.
[43]	TOJA P M，BRANZI G，CIAMBELLOTTI F，et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure[J]. Clin Endocrinol （Oxf），2012，76（3）：332-338. DOI：10.1111/j.1365-2265.2011.04206.x.
[44]	NTALI G，HAKAMI O，WATTEGAMA M，et al. Mortality of patients with Cushing's disease[J]. Exp Clin Endocrinol Diabetes，2021，129（3）：203-207. DOI：10.1055/a-1197-6380.
[45]	CLAYTON R N，JONES P W，REULEN R C，et al. Mortality in patients with Cushing's disease more than 10 years after remission：a multicentre，multinational，retrospective cohort study[J]. Lancet Diabetes Endocrinol，2016，4（7）：569-576. DOI：10.1016/S2213-8587(16)30005-5.
[46]	MAZZIOTTI G，FRARA S，GIUSTINA A. Pituitary diseases and bone[J]. Endocr Rev，2018，39（4）：440-488. DOI：10.1210/er.2018-00005.
[47]	BRAUN L T，FAZEL J，ZOPP S，et al. The effect of biochemical remission on bone metabolism in Cushing's syndrome：a 2-year follow-up study[J]. J Bone Miner Res，2020，35（9）：1711-1717. DOI：10.1002/jbmr.4033.
[48]	SCILLITANI A，MAZZIOTTI G，DI SOMMA C，et al. Treatment of skeletal impairment in patients with endogenous hypercortisolism：when and how? [J]. Osteoporos Int，2014，25（2）：441-446. DOI：10.1007/s00198-013-2588-y.
[49]	TZANELA M，KARAVITAKI N，STYLIANIDOU C，et al. Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome[J]. Clin Endocrinol （Oxf），2004，60（3）：309-314. DOI：10.1046/j.1365-2265.2004.01976.x.
[50]	WEBB S M，MO D J，LAMBERTS S W J，et al. Metabolic，cardiovascular，and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma[J]. J Clin Endocrinol Metab，2010，95（2）：630-638. DOI：10.1210/jc.2009-0806.
[51]	MATHIOUDAKIS N，PENDLETON C，QUINONES-HINOJOSA A，et al. ACTH-secreting pituitary adenomas：size does not correlate with hormonal activity[J]. Pituitary，2012，15（4）：526-532. DOI：10.1007/s11102-011-0362-8.
[52]	FORMENTI A M，MAFFEZZONI F，DOGA M，et al. Growth hormone deficiency in treated acromegaly and active Cushing's syndrome[J]. Best Pract Res Clin Endocrinol Metab，2017，31（1）：79-90. DOI：10.1016/j.beem.2017.03.002.
[53]	VOGEL F，BRAUN L T，RUBINSTEIN G，et al. Persisting muscle dysfunction in Cushing's syndrome despite biochemical remission[J]. J Clin Endocrinol Metab，2020，105（12）：dgaa625. DOI：10.1210/clinem/dgaa625.
[54]	BRIDE M M，CRESPO I，WEBB S M，et al. Quality of life in Cushing's syndrome[J]. Best Pract Res Clin Endocrinol Metab，2021，35（1）：101505. DOI：10.1016/j.beem.2021.101505.
[55]	STROUD A，DHALIWAL P，ALVARADO R，et al. Outcomes of pituitary surgery for Cushing's disease：a systematic review and meta-analysis[J]. Pituitary，2020，23（5）：595-609. DOI：10.1007/s11102-020-01066-8.
[56]	朱蕾蕾，余叶蓉，肖珍，等. 清晨血皮质醇及促肾上腺皮质激素水平用作库欣病经蝶术后缓解标准的临床价值[J]. 四川大学学报：医学版，2019，50（2）：260-263. DOI：10.13464/j.scuxbyxb.2019.02.024.
[57]	PETERSENN S，BECKERS A，FERONE D，et al. Therapy of endocrine disease：outcomes in patients with Cushing's disease undergoing transsphenoidal surgery：systematic review assessing criteria used to define remission and recurrence[J]. Eur J Endocrinol，2015，172（6）：R227-239. DOI：10.1530/EJE-14-0883.
[58]	ALEXANDRAKI K I，KALTSAS G A，ISIDORI A M，et al. Long-term remission and recurrence rates in Cushing's disease：predictive factors in a single-centre study[J]. Eur J Endocrinol，2013，168（4）：639-648. DOI：10.1530/EJE-12-0921.
[59]	BROERSEN L H A，BIERMASZ N R，VAN FURTH W R，et al. Endoscopic vs. microscopic transsphenoidal surgery for Cushing's disease：a systematic review and meta-analysis[J]. Pituitary，2018，21（5）：524-534. DOI：10.1007/s11102-018-0893-3.
[60]	HONEGGER J，GRIMM F. The experience with transsphenoidal surgery and its importance to outcomes[J]. Pituitary，2018，21（5）：545-555. DOI：10.1007/s11102-018-0904-4.
[61]	PIVONELLO R，DE LEO M，COZZOLINO A，et al. The treatment of Cushing's disease[J]. Endocr Rev，2015，36（4）：385-486. DOI：10.1210/er.2013-1048.
[62]	HINOJOSA-AMAYA J M，VARLAMOV E V，MCCARTNEY S，et al. Hypercortisolemia recurrence in Cushing's disease；a diagnostic challenge[J]. Front Endocrinol （Lausanne），2019，10：740. DOI：10.3389/fendo.2019.00740.
[63]	ARAUJO-CASTRO M，GARCÍA CANO A，JIMÉNEZ MENDIGUCHÍA L，et al. Diagnostic accuracy of the different hormonal tests used for the diagnosis of autonomous cortisol secretion[J]. Sci Rep，2021，11（1）：20539. DOI：10.1038/s41598-021-00011-4.

检查项目		灵敏度（%）	特异度（%）	优、缺点
CS诊断指标
	1 mg-DST	98	81	优点：阴性预测值高；易于医疗人员管理缺点：假阳性率高；地塞米松代谢可影响测定结果；其他药物干扰
	24 hUFC	91.0	81.5	优点：参考范围广缺点：操作繁琐；样本之间的多变性可能为50%，需要留取2~3个样本
	LNSC	97.0	97.5	优点：患者易于操作；应提醒患者在收集唾液样本15 min前不要进食、饮水、吸烟或刷牙缺点：多变性；根据参考实验室的不同，临界值会有很大的不同；可能被局部氢化可的松污染；并非所有中心均能检测
CD复发监测
	LNSC	75~90	93~95	优点：多数患者LNSC的异常早于DST和24 hUFC的异常缺点：多变性；易出现正常或阴性结果
	24 hUFC	68	100	优点：相对便捷缺点：大约50%存在变异；容易受体积计量影响而导致异常结果
	DDAVP刺激试验	68	95	优点：可预测存在促肾上腺皮质激素腺瘤；临床腺瘤复发前可以变阳性缺点：多次采血，动态密集检测
	1 mg-DST	NA	NA	优点：可能会在24 hUFC之前出现异常缺点：评估复发效用方面的证据有限

检查项目		灵敏度（%）	特异度（%）	优、缺点
CS诊断指标
	1 mg-DST	98	81	优点：阴性预测值高；易于医疗人员管理缺点：假阳性率高；地塞米松代谢可影响测定结果；其他药物干扰
	24 hUFC	91.0	81.5	优点：参考范围广缺点：操作繁琐；样本之间的多变性可能为50%，需要留取2~3个样本
	LNSC	97.0	97.5	优点：患者易于操作；应提醒患者在收集唾液样本15 min前不要进食、饮水、吸烟或刷牙缺点：多变性；根据参考实验室的不同，临界值会有很大的不同；可能被局部氢化可的松污染；并非所有中心均能检测
CD复发监测
	LNSC	75~90	93~95	优点：多数患者LNSC的异常早于DST和24 hUFC的异常缺点：多变性；易出现正常或阴性结果
	24 hUFC	68	100	优点：相对便捷缺点：大约50%存在变异；容易受体积计量影响而导致异常结果
	DDAVP刺激试验	68	95	优点：可预测存在促肾上腺皮质激素腺瘤；临床腺瘤复发前可以变阳性缺点：多次采血，动态密集检测
	1 mg-DST	NA	NA	优点：可能会在24 hUFC之前出现异常缺点：评估复发效用方面的证据有限

Interpretation of Consensus on Diagnosis and Management of Cushing's Disease: a Guideline Update of the International Pituitary Society——Diagnosis

国际垂体协会《库欣病的诊断和管理共识（更新版）》解读——诊断篇

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 63

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Peng, LIU Lidi, ZHANG Ying, YANG Ziyu, LIU Changming, TANG Yijun, LIAO Xiaoyang, JIA Yu. Interpretation and Clinical Implications of the 2024 Italian Guidelines for the Management of Adult Individuals with Overweight and Obesity and Metabolic Comorbidities That are Resistant to Behavioral Treatment [J]. Chinese General Practice, 2025, 28(30): 3747-3752.
[2]	ZHANG Tianyu, YU Haibo, CHEN Fei, LI Xin, ZHANG Jiajia, ZHAN Xiaokai, SHEN Man, TANG Ran, FAN Sibin, ZHAO Fengyi, HUANG Zhongxia. Meta-analysis of the Efficacy and Safety of Systemic Treatment for POEMS Syndrome [J]. Chinese General Practice, 2025, 28(27): 3447-3455.
[3]	CUI Yiyuan, YAN Yijing, WANG Ying, MENG Xiangju, ZHANG Qinglin, LIU Lixing, LI Sicong, FENG Li, The Working Group for the Clinical Practice Guideline for the Cancer-related Fatigue with Integrated Traditional Chinese and Western Medicine. Clinical Practice Guideline for the Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Cancer-related Fatigue [J]. Chinese General Practice, 2025, 28(27): 3345-3358.
[4]	WANG Yajing, DUAN Xiaoyang, HOU Ran, HUANG Yajie, SHI Jian. Advances in Targeted Combination Therapy for Patients with Brain Metastases from EGFR-mutated Non-small Cell Lung Cancer [J]. Chinese General Practice, 2025, 28(26): 3328-3337.
[5]	HUANG Yulin, WANG Haoyun, LI Yanmei, XIAO Xueying. Symptom Clusters in Gastric Cancer Patients Receiving Chemotherapy: a Scoping Review [J]. Chinese General Practice, 2025, 28(26): 3338-3344.
[6]	ZHI Congcong, LI Xue, CHENG Yicheng, WANG Xiaolong, ZHENG Lihua. Guidelines for Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment of Hemorrhoids (2025 Edition) [J]. Chinese General Practice, 2025, 28(26): 3217-3228.
[7]	RUAN Wanbai, LI Junfeng, YIN Yanmei, PENG Lei, ZHU Kexiang. Research Progress of Targeted Therapy and Immunotherapy for Pancreatic Cancer [J]. Chinese General Practice, 2025, 28(23): 2950-2960.
[8]	YANG Handan, QIAO Wen, HE Shu, CHEN Yi, TONG Yunmei. The Impact of Acceptance and Commitment Therapy Combined with Sertraline on Depressive Mood, Suicidal Ideation, and Sleep Quality of Adolescents with Depression [J]. Chinese General Practice, 2025, 28(22): 2813-2818.
[9]	WANG Ying, YAN Yijun, LIU Lei, HU Yumin, ZHANG Yang, LIU Kai, JIANG Boren. Effects of Resistance Exercise Combined with Nutritional Intervention on Blood Glucose Stability in Elderly Patients with Type 2 Diabetes Mellitus with Sarcopenia [J]. Chinese General Practice, 2025, 28(21): 2604-2610.
[10]	Chinese Geriatrics Society, General Practice Branch of Zhejiang Medical Association, the Expert Collaboration Group on Medically Unspecified Disease in General Practice. Expert Consensus on the Diagnosis, Treatment, and Management of Emaciation (2025) [J]. Chinese General Practice, 2025, 28(21): 2577-2594.
[11]	YANG Jiang, LI Jiansheng, CHEN Yaolong, LIU Huiguo, WANG Jianxin, YU Jiajie, LI Huiru, XIAO Qionghua, XIE Yang, LI Suyun, WANG Minghang. Guideline on Treating Adult Community-acquired Pneumonia with Chinese Patent Medicines (2025 Edition) [J]. Chinese General Practice, 2025, 28(20): 2464-2480.
[12]	LUO Yunzhao, JIANG Hongchuan, XU Feng. Predicting Response to Neoadjuvant Therapy in Breast Cancer Using Deep Learning on Primary Core Needle Biopsy Slides [J]. Chinese General Practice, 2025, 28(19): 2407-2413.
[13]	GU Jie, HUANG Yanyan. Diagnosis and Comprehensive Management of Rare Diseases: the Indispensable Role of General Practitioners [J]. Chinese General Practice, 2025, 28(16): 1955-1960.
[14]	SUI Hongping, LI Tingting, JIANG Tongtong, XIA Yunlong, SHI Tieying. Research Progress on Blood Pressure Management of Vascular Endothelial Growth Factor Signaling Pathway Inhibitor-related Hypertension [J]. Chinese General Practice, 2025, 28(15): 1932-1936.
[15]	SHI Jian, WANG Yajing, HOU Ran, HUANG Yajie, DUAN Xiaoyang. Efficacy and Safety of EGFR-TKI Combined with Chemotherapy for the First-line Treatment of EGFR-mutated Advanced Non-small Cell Lung Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(11): 1383-1394.